Pfizer agreed to acquire Hospira for $90 per share in cash, total enterprise value approximately $17B, expanding Pfizer's established drug business and adding global leadership in injectables, infusion technologies, and biosimilars. Closed September 3, 2015.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Mixed
Assessment window: 10yr post-close.
Key facts
AnnouncedFeb 05, 2015
ClosedSep 03, 2015
Deal value$17.0B
Deal typeAcquisition/Merger
Therapeutic areaMultiple (oncology, supportive care, anti-infectives)
IndicationsMultiple (oncology, supportive care, anti-infectives)
Key assetsSterile injectables and biosimilars portfolio (Inflectra/Remsima, Retacrit, Nivestim)
MechanismGeneric sterile injectables and biosimilar monoclonal antibodies/proteins